Item 1.02 Termination of a Material Definitive Agreement.
On
PRS-080 drug candidate targeting hepcidin in
--------------------------------------------------------------------------------
© Edgar Online, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.811 USD | +3.49% |
|
+7.93% | -32.62% |
15/05 | Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
19/04 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
Item 1.02 Termination of a Material Definitive Agreement.
On
PRS-080 drug candidate targeting hepcidin in
--------------------------------------------------------------------------------
© Edgar Online, source
1st Jan change | Capi. | |
---|---|---|
-32.62% | 12.52M | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |